Compare Prologis Inc (PLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Sana Biotechnology Inc — how do they compare? Prologis Inc trades at $135.62 (market cap $128.92B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Prologis Inc is far larger — about 136.1× Sana Biotechnology Inc's market cap, and Prologis Inc pays a 3.15% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PLD | SANA | |
|---|---|---|
Market Cap | $128.92B | $947.48M |
Sector | Real Estate | Health |
52-Week High | $149.96 | $5.92 |
52-Week Low | $110.98 | $2.68 |
Enterprise Value | $163.66B | $860.73M |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue grew to $8.79B in 2025, and the company maintains high profit margins. Analyst consensus is bullish with a $160.13 price target, though technical indicators show near-term pressure with support at $137.
The outlook for PLD is positive due to consistent earnings beats and robust institutional interest, but risks include rising debt levels and market volatility. The stock offers growth potential from its real estate portfolio, yet investors should monitor debt-to-asset trends and economic conditions affecting REIT valuations.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
